Journal Article

IV.6.1 Post‐transplant lymphoproliferative disease (PTLD): prevention and treatment

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 17, issue suppl_4, pages 31-31
Published in print April 2002 | ISSN: 0931-0509
Published online April 2002 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/17.suppl_4.31-b
IV.6.1 Post‐transplant lymphoproliferative disease (PTLD): prevention and treatment

Show Summary Details

Preview

Guidelines

A. In the first year after organ transplantation, recipients are at the greatest risk of developing lymphoproliferative diseases (PTLDs), which are induced most often by Epstein–Barr virus (EBV) infection, and patients should therefore be screened prior to or at the time of transplantation for EBV antibodies.

(Evidence level B)

B. In the rare cases (<5%) where the recipient is EBV seronegative, he or she has a 95% likelihood of receiving an organ from an EBV‐seropositive donor, which translates into a high risk of primary EBV infection with seroconversion soon after transplantation. In such cases, the recipient should receive a prophylactic antiviral treatment with acyclovir, valacyclovir or ganciclovir, starting at the time of transplant and lasting for at least 3 months. The specific recommendations given for CMV prophylaxis could be applicable in this situation. (See also Guidelines in Part 1: III.8.1, p. 87.)

(Evidence level C)

C. The treatment of PTLD should be based on accurate pathology with extensive cell markers and phenotyping. The treatment modalities are as follows.

Reduction of basal immunosuppression in all cases (either maintain only steroids, or decrease by at least 50% the anti‐calcineurin drugs and stop other immunosuppressive drugs).

(Evidence level B)

In the case of EBV‐positive B‐cell lymphoma, antiviral treatment with acyclovir, valacyclovir or ganciclovir may be initiated for at least 1 month or according to the blood level of EBV replication when available.

(Evidence level C)

In the case of rare lymphomas from the mucosal‐associated lymphoid tissue (MALT) with positive Helicobacter pylori, full eradication of H. pylori should be carried out with a validated protocol. Subsequent H. pylori prophylaxis should be implemented to avoid relapse.

(Evidence level B)

In the case of CD20‐positive lymphomas, treatment with rituximab, a chimeric monoclonal antibody directed against CD20, should be carried out with one i.v. injection per week for 4 weeks.

(Evidence level B)

In the case of diffuse lymphomas or improper response to previous treatment, CHOP chemotherapy should be used alone or in combination with rituximab. The CHOP regimen is cyclophosphamide, doxorubicine, vincristine and prednisone.

(Evidence level B)

Complete cessation of immunosuppression with or without graft nephrectomy should also be considered.

(Evidence level C)

Journal Article.  0 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.